Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)